Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13913048 | 0.85 | ALOX15 (0.33) | MAPK1ALOX15TDP1 | |
| SCHEMBL4109201 | 0.78 | ALOX15 (0.43) | NPC1LMNAMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL13903365 | 0.72 | ALOX15 (0.42) | NPC1CASP3RAB9ASMN1; SMN2SENP8 | |
| SCHEMBL2609650 | 0.71 | NPC1 (0.38) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL11848883 | 0.69 | ALOX15 (0.39) | MAPK1ALOX15TDP1 | |
| SCHEMBL18430311 | 0.67 | ALOX15 (0.33) | MAPK1ALOX15TDP1 | |
| SCHEMBL14232052 | 0.66 | GRIN2D (0.35) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL11806035 | 0.65 | GABRA1 (0.44) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL22663768 | 0.64 | NPC1 (0.47) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL11510152 | 0.64 | ALOX15 (0.34) | ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | NPC1 2018/4885LMNA 2779/4885MAPK1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.